Oculis Acquires Accure's Privosegtor And ACT-02 Assets In Deal Worth $3.8M Upfront Cash And Up To 2,050,000 Shares
Benzinga Newsdesk 2 months ago
News
Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at closing and up to
- Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creation
- Transaction consideration includes $3.8 million up-front cash payment at closing and up to 2,050,000 Oculis ordinary shares subject to lockup release over a period of up to 2 years, or vesting upon achievement of development and regulatory milestones
- Privosegtor, a neuroprotective drug candidate, is currently being investigated in registrational trials with initial indications of optic neuropathies and acute multiple sclerosis (MS) relapses Investigational New Drug (IND) submission being prepared for Q4 2026